scholarly journals Rapamycin‐based graft‐ versus ‐host disease prophylaxis increases the immunosuppressivity of myeloid‐derived suppressor cells without affecting T cells and anti‐tumor cytotoxicity

2020 ◽  
Vol 202 (3) ◽  
pp. 407-422
Author(s):  
J. Scheurer ◽  
T. Reisser ◽  
F. Leithäuser ◽  
J. J. Messmann ◽  
K. Holzmann ◽  
...  
Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5716-5716
Author(s):  
Yigeng Cao ◽  
Ming-Zhe Han ◽  
Peng Liu ◽  
Haiyan Gong ◽  
Haiyan Zhu ◽  
...  

Abstract Allogeneic HSCT (allo-HSCT) is associated with serious side effects and its most common complication is graft-versus-host disease (GVHD). Hyperacute GVHD is a clinical syndrome that occurs within the first 14 days after allo-HSCT associated with significant morbidity and mortality. The large sample size of clinical study indicated that the incidence of hyperacute GVHD in patient who underwent an allo-HSCT was about 9%, but the pathological process and crucial factor of this complication have incompletely defined. Myeloid-derived suppressor cells (MDSCs) have been found that had a beneficial role in treatment of GVHD, on account of suppressing ability on alloreactive T-cell-response in vitro and in vivo. It was reported that reactive oxygen species (ROS) have been implicated in MDSCs-mediated T cell suppression and MDSCs from NOX2-deficient mice, chronic granulomatous disease (CGD) mice, failed to suppress T cell function. However, the investigation of whether and how MDSCs and ROS play in CGD mice receiving allo-HSCT is lacking. In our research, WT mice receiving allo-HSCT began to appear typical acute GVHD clinical manifestations in about 20 days and died within 30 days after transplantation, while CGD mice receiving allo-HSCT suddenly suffered from hyperacute GVHD at day 3 after allo-HSCT: performed continuous weight loss, demonstrated poor grooming and impairs movement with or without hunching or skin integrated and animals died within 2 days after onset of symptoms. Further study shown that the donor spleen derived T cells was indispensable for hyperacute GVHD of CGD mice after receiving allo-HSCT. T lymphocyte subsets and proportional change in bone marrow and spleen of each group were detected by flow cytommeter after transplantation. The percentage and absolute number of donor derived CD3+CD8+T cell from both BM and spleen of CGD were significant higher than that of WT mice received allo-HSCT. Moreover, cell size and expression of activation marker CD25, CD44, and CD69 of CD3+CD8+T cell from both BM and spleen of CGD mice were significant higher than that of WT mice. The killing ability of donor derived CD3+T cells was observed by the living cells workstation and it was obviously to see that allo-reactive T cells from CGD mice had stronger killing ability. The levels of different cytokines in serum of recipient mice were detected by protein chip at day 3 after allo-HSCT. Comparing to C57BL/6 mice, more than ten kinds of inflammatory factors, including IL-6, were increased in the serum of CGD mice, which indicated that the cytokine storm related to T cells might be occur during hyperacute GVHD. In addition, using this hyperacute mouse model, we revealed that application of ROS agonist, L-buthionine-S, R-sulfoximine (BSO), rescued the CGD mice receiving allo-HSCT from hyperacute GVHD. In General, this study pioneering established a stable murine model of hyperacute GVHD and proved that allo-reactive T cells massively activated and proliferated since ROS production defective MDSCs lose the ability of inhibiting T cell immune reaction and caused hyperacute GVHD. These data provided new insights into the pathogenesis of GVHD and may improve the clinical management of this common complication. Disclosures No relevant conflicts of interest to declare.


2012 ◽  
Vol 33 (3) ◽  
pp. 259-267 ◽  
Author(s):  
Hyo Jin Park ◽  
Dahye Byun ◽  
An Hi Lee ◽  
Ju Hyun Kim ◽  
Young Larn Ban ◽  
...  

2021 ◽  
Vol 10 (10) ◽  
pp. 2050
Author(s):  
Christos Demosthenous ◽  
Ioanna Sakellari ◽  
Vassiliki Douka ◽  
Penelope Georgia Papayanni ◽  
Achilles Anagnostopoulos ◽  
...  

Background: Myeloid-derived suppressor cells (MDSCs) are implicated in the complex interplay involving graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) in hematologic malignancies. Methods: A review of literature through PubMed was undertaken to summarize the published evidence on the pathophysiology and clinical implications of MDSCs in allo-HCT. Literature sources published in English since 1978 were searched, using the terms Natural Suppressor (NS) cells, MDSCs, GVHD, and allo-HCT. Results: In vivo studies demonstrated that MDSCs derived from mobilization protocols could strongly suppress allo-responses mediated by T cells and enhance T-Reg activity, thus inhibiting GVHD toxicity. However, the influence of MDSCs on the GVL effect is not fully defined. Conclusions: The induction or maintenance of MDSC suppressive function would be advantageous in suppressing inflammation associated with GVHD. Pathways involved in MDSC metabolism and the inflammasome signaling are a promising field of study to elucidate the function of MDSCs in the pathogenesis of GVHD and translate these findings to a clinical setting.


2021 ◽  
Vol 12 ◽  
Author(s):  
Lin Li ◽  
Jin Yin ◽  
Yun Li ◽  
Chunyan Wang ◽  
Xia Mao ◽  
...  

We compared the effectiveness and safety of pegylated granulocyte colony-stimulating factor (peg-G-CSF) vs. non-peg-G-CSF for hematopoietic stem cell mobilization in allogeneic hematopoietic stem cell transplantation in a real-world setting. We included 136 consecutive healthy donors treated with non–peg-G-CSF (n = 53) or peg-G-CSF (n = 83), and 125 consecutive recipients (n = 42 and 83, respectively) in this study. All harvesting was completed successfully. No significant difference in leukapheresis number and adverse events frequency was observed, nor were there severe adverse events leading to discontinuation of mobilization. The leukapheresis products mobilized by peg-G-CSF had higher total nucleated cells (p < 0.001), monocytic myeloid-derived suppressor cells (p < 0.001), granulocytic myeloid-derived suppressor cells (p = 0.004) and B cells (p = 0.019). CD34+ cells and other lymphocyte subsets (T cells, regulatory T cells, natural killer [NK] cells, etc.) were similar in both apheresis products. Patients who received grafts mobilized by peg-G-CSF exhibited a lower incidence of grade III-IV acute graft-versus-host disease (p = 0.001). The 1-year cumulative incidence of chronic graft-versus-host disease and relapse, 1-year probability of graft-versus-host disease-free relapse-free survival, and overall survival did not differ significantly between subgroups. Our results suggest that collecting allogeneic stem cells after the administration of peg-G-CSF is feasible and safe. Peg-G-CSF mobilized grafts may reduce severe acute graft-versus-host disease compared with non-peg-G-CSF mobilized grafts after allogeneic stem cell transplantation. The beneficial effects of a peg-G-CSF graft might be mediated by increased numbers of monocytic myeloid-derived suppressor cells.


2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Min-Jung Park ◽  
Jin-Ah Baek ◽  
Se-Young Kim ◽  
Kyung-Ah Jung ◽  
Jeong Won Choi ◽  
...  

Abstract Background Myeloid-derived suppressor cells (MDSCs) play a critical role in modulating the immune response and promoting immune tolerance in models of autoimmunity and transplantation. Regulatory T cells (Tregs) exert therapeutic potential due to their immunomodulatory properties, which have been demonstrated both in vitro and in clinical trials. Cell-based therapy for acute graft-versus-host disease (aGVHD) may enable induction of donor-specific tolerance in the preclinical setting. Methods We investigated whether the immunoregulatory activity of the combination of MDSCs and Tregs on T cell and B cell subset and alloreactive T cell response. We evaluated the therapeutic effects of combined cell therapy for a murine aGVHD model following MHC-mismatched bone marrow transplantation. We compared histologic analysis from the target tissues of each groups were and immune cell population by flow cytometric analysis. Results We report a novel approach to inducing immune tolerance using a combination of donor-derived MDSCs and Tregs. The combined cell-therapy modulated in vitro the proliferation of alloreactive T cells and the Treg/Th17 balance in mice and human system. Systemic infusion of MDSCs and Tregs ameliorated serverity and inflammation of aGVHD mouse model by reducing the populations of proinflammatory Th1/Th17 cells and the expression of proinflammatory cytokines in target tissue. The combined therapy promoted the differentiation of allogeneic T cells toward Foxp3 + Tregs and IL-10-producing regulatory B cells. The combination treatment control also activated human T and B cell subset. Conclusions Therefore, the combination of MDSCs and Tregs has immunomodulatory activity and induces immune tolerance to prevent of aGVHD severity. This could lead to the development of new clinical approaches to the prevent aGVHD.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4019-4019
Author(s):  
Gudrun Strauss ◽  
Natalie Hartmann ◽  
Michael Kluge ◽  
Harald Fricke ◽  
Klaus-Michael Debatin

Abstract Abstract 4019 Allogeneic bone marrow transplantation (BMT) is a curative treatment modality for haematological malignancies since mature allogeneic T cells in the transplant efficiently eliminate residual tumor cells (graft-versus-tumor (GVT) effect). However, these donor T cells are also responsible for the induction of graft-versus-host disease (GVHD) by attacking recipient tissue leading to significant morbidity and mortality. Interfering with T cell effector mechanisms responsible for GVHD-induction without preventing T cell functions towards third-party or opportunistic pathogens and while maintaining anti-tumor cytotoxicity might lead to new treatment strategies after allogeneic BMT. The CD95/CD95L system significantly contributes to GVHD-associated tissue damage and intervention into this signaling pathway might therefore inhibit GVHD-development without disturbing the GVT-effect. APG101 is a human soluble fusion protein consisting of the extracellular domain of CD95 and the Fc portion of IgG blocking the interaction of CD95L with its cognate receptor. We tested the effect of APG101 on T cell function, GVHD development and anti-tumor cytotoxicity in an allogeneic parent into F1 (C57BL/6 (B6) (H-2b) into B6D2F1 (H-2bxd)) BMT model with a mismatch in HLA-Class I and II molecules. In vitro, APG101 efficiently inhibited CD95L-mediated apoptosis of primary naïve mouse CD4+ and CD8+ T cells but did not interfere with their proliferative or cytotoxic capacity. To test APG101 as a therapeutic agent in BMT we induced acute GVHD in lethally irradiated B6D2F1 mice by transplantation of B6-derived BM together with allogeneic spleen cells. APG101 treatment was conducted intraperitoneally twice a week until the end of the experiment, starting either one day before BMT (= prophylactic treatment) or starting six or thirteen days after BMT (= therapeutic treatment). Prophylactic and early (day 6), but not late therapeutic treatment (day 13), effectively protected recipients from clinical GVHD and significantly improved survival. Although APG101 efficiently prevented GVHD-induction, homing and proliferation of allogeneic T cells into lymphoid organs and GVHD-target organs was unaltered compared to non-treated animals. Since CD95L is also known as a reverse signaling co-stimulator in T cell activation, APG101 might interfere with T cell function in vivo. However, no differences in phenotype, proliferation or cytokine expression of transplanted allogeneic T cells was observed in APG101-treated mice compared to non-treated mice. Most importantly, the GVT effect was preserved in APG101-treated mice. Anti-tumor cytotoxicity of transplanted allogeneic T cells was not abrogated by APG101 injection independent whether the murine mastocytoma cell line P815 or Bcr-Abl transduced primary B-ALL cells were injected. In summary, our findings convincingly show that early APG101 treatment is a promising approach to prevent GVHD without abrogating T cell effector functions and while preserving the GvT effect after allogeneic BMT. Disclosures: Strauss: Apogenix: Research Funding. Hartmann:Apogenix: Research Funding. Kluge:Apogenix: Employment. Fricke:Apogenix GmbH: Employment, Equity Ownership. Debatin:Apogenix GmbH: Patents & Royalties, Research Funding.


Sign in / Sign up

Export Citation Format

Share Document